{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T19:43:25Z","timestamp":1785786205250,"version":"3.56.0"},"reference-count":21,"publisher":"Royal College of General Practitioners","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BJGP Open"],"accepted":{"date-parts":[[2023,12,14]]},"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>During the COVID-19 pandemic many patients were switched from warfarin to direct-acting oral anticoagulants (DOACs), which require the creatinine clearance (CrCl) calculated to ensure the correct dose is prescribed to avoid bleeding or reduced efficacy.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Aim<\/jats:title>\n<jats:p>To identify the study population proportion prescribed a DOAC. Of these, the proportion with recorded: weight, estimated glomerular filtration rate (eGFR), creatinine, CrCl and atrial fibrillation (AF). To analyse the proportion of patients with recorded AF and CrCl prescribed a recommended DOAC dose.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Design &amp; setting<\/jats:title>\n<jats:p>A retrospective cohort study of 20.5 million adult NHS patients\u2019 electronic health records (EHRs) in England in the OpenSAFELY-TPP platform (January 2018\u2013February 2023).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Method<\/jats:title>\n<jats:p>Patients on DOACs were analysed for age, sex, recorded weight, eGFR, creatinine, CrCl and AF. Prescribed DOAC doses in patients with recorded AF were compared with recommended doses for recorded CrCl and determined as either recommended, higher than recommended (overdose), or lower than recommended (underdose).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>In February 2023, weight, eGFR, creatinine, CrCl, and AF were recorded in 72.8%, 92.4%, 94.3%, 73.5%, and 73.9% of study population, respectively. Both AF and CrCl were recorded for 56.7% of patients. Of these, 86.2% received the recommended, and 13.8% non-recommended, DOAC doses.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>CrCl is not recorded for a substantial number of patients on DOACs. We recommend that national organisations tasked with safety, collectively update guidance on the appropriate weight to use in the Cockcroft\u2013Gault equation, clarify that CrCl is not equivalent to eGFR, and work with GP clinical system suppliers to standardise the calculation of CrCl in the EHR.<\/jats:p>\n<\/jats:sec>","DOI":"10.3399\/bjgpo.2023.0163","type":"journal-article","created":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T13:15:10Z","timestamp":1706793310000},"page":"BJGPO.2023.0163","source":"Crossref","is-referenced-by-count":4,"title":["Safety of direct-acting oral anticoagulant (DOAC) prescribing: OpenSAFELY-TPP analysis of 20.5 million adults\u2019 electronic health records"],"prefix":"10.3399","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2908-2308","authenticated-orcid":false,"given":"Karen","family":"Homan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Seeley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0295-3812","authenticated-orcid":false,"given":"Louis","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sajida","family":"Khatri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Jamieson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5064-9375","authenticated-orcid":false,"given":"Victoria","family":"Speed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol A","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Mehrkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Bacon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3786-9063","authenticated-orcid":false,"given":"Brian","family":"MacKenna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Goldacre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1987","published-online":{"date-parts":[[2024,2,1]]},"reference":[{"key":"2024090602151008000_8.2.BJGPO.2023.0163.1","unstructured":"NHS England NHS Improvement (2020) Clinical guide for the management of anticoagulant services during the coronavirus pandemic, accessed. https:\/\/www.nice.org.uk\/Media\/Default\/About\/COVID-19\/Specialty-guides\/specialty-guide-anticoagulant-services-and-coronavirus.pdf. 14 Mar 2024."},{"key":"2024090602151008000_8.2.BJGPO.2023.0163.2","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-021-02416-4"},{"issue":"11","key":"2024090602151008000_8.2.BJGPO.2023.0163.3","article-title":"Direct-acting oral anticoagulants (DOACs): reminder of bleeding risk, including availability of reversal agents","year":"2020","journal-title":"Drug Safety Update"},{"key":"2024090602151008000_8.2.BJGPO.2023.0163.4","unstructured":"Joint Formulary Committee British National Formulary [online] (London: BMJ Group and Pharmaceutical press). 2024. accessed. http:\/\/www.medicinescomplete.com. 14 Mar 2024."},{"key":"2024090602151008000_8.2.BJGPO.2023.0163.5","article-title":"Prescribing medicines in renal impairment using the appropriate estimate of renal function to avoid the risk of adverse drug reactions","year":"2019","journal-title":"Drug Safety Update"},{"key":"2024090602151008000_8.2.BJGPO.2023.0163.6","unstructured":"National Institute for Health and Care Excellence (NICE) Anticoagulation \u2014 oral. 2023. accessed. https:\/\/cks.nice.org.uk\/topics\/anticoagulation-oral\/. 14 Mar 2024."},{"key":"2024090602151008000_8.2.BJGPO.2023.0163.7","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2021-001784"},{"key":"2024090602151008000_8.2.BJGPO.2023.0163.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2022.01.023"},{"key":"2024090602151008000_8.2.BJGPO.2023.0163.9","unstructured":"NICE Scenario: Edoxaban. 2023. accessed. https:\/\/cks.nice.org.uk\/topics\/anticoagulation-oral\/management\/edoxaban\/. 14 Mar 2024."},{"key":"2024090602151008000_8.2.BJGPO.2023.0163.10","unstructured":"NHS Business Services Authority (2023) Pseudo anonymised patient level prescribed and dispensed data set January 2018 to February 2023, accessed April 2023."},{"key":"2024090602151008000_8.2.BJGPO.2023.0163.11","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-022-02368-y"},{"key":"2024090602151008000_8.2.BJGPO.2023.0163.12","unstructured":"NHS England (2021) Annex B \u2013 Investment and Impact Fund (IIF): 2021\/22 and 2022\/23, accessed. https:\/\/www.england.nhs.uk\/wp-content\/uploads\/2021\/08\/B0828-iii-annex-b-investment-and-impact-fund-21-22-22-23.pdf. 14 Mar 2024."},{"key":"2024090602151008000_8.2.BJGPO.2023.0163.13","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14127"},{"key":"2024090602151008000_8.2.BJGPO.2023.0163.14","doi-asserted-by":"publisher","DOI":"10.1136\/dtb.2019.000013"},{"key":"2024090602151008000_8.2.BJGPO.2023.0163.15","doi-asserted-by":"publisher","DOI":"10.1159\/000180580"},{"key":"2024090602151008000_8.2.BJGPO.2023.0163.16","unstructured":"NHS England (2023) The NHS England OpenSAFELY COVID-19 service \u2014 privacy notice. accessed. https:\/\/digital.nhs.uk\/coronavirus\/coronavirus-covid-19-response-information-governance-hub\/the-nhs-england-opensafely-covid-19-service-privacy-notice. 14 Mar 2024."},{"key":"2024090602151008000_8.2.BJGPO.2023.0163.17","unstructured":"NHS England (2023) Data security and protection toolkit. accessed. https:\/\/digital.nhs.uk\/data-and-information\/looking-after-information\/data-security-and-information-governance\/data-security-and-protection-toolkit. 14 Mar 2024."},{"key":"2024090602151008000_8.2.BJGPO.2023.0163.18","unstructured":"NHS England (2022) ISB1523: Anonymisation standard for publishing health and social care data. accessed. https:\/\/digital.nhs.uk\/data-and-information\/information-standards\/information-standards-and-data-collections-including-extractions\/publications-and-notifications\/standards-and-collections\/isb1523-anonymisation-standard-for-publishing-health-and-social-care-data. 14 Mar 2024."},{"key":"2024090602151008000_8.2.BJGPO.2023.0163.19","unstructured":"Department of Health and Social Care (2022) [Withdrawn] Coronavirus (COVID-19): notice under regulation 3(4) of the Health Service (Control of Patient Information) Regulations 2002 \u2014 general. accessed. https:\/\/www.gov.uk\/government\/publications\/coronavirus-covid-19-notification-of-data-controllers-to-share-information\/coronavirus-covid-19-notice-under-regulation-34-of-the-health-service-control-of-patient-information-regulations-2002-general--2. 14 Mar 2024."},{"key":"2024090602151008000_8.2.BJGPO.2023.0163.20","unstructured":"NHS England (2020) COVID-19 public health directions 2020. accessed. https:\/\/digital.nhs.uk\/about-nhs-digital\/corporate-information-and-documents\/directions-and-data-provision-notices\/secretary-of-state-directions\/covid-19-public-health-directions-2020. 14 Mar 2024."},{"key":"2024090602151008000_8.2.BJGPO.2023.0163.21","unstructured":"NHS Health Research Authority (2023) Confidentiality Advisory Group, accessed. https:\/\/www.hra.nhs.uk\/about-us\/committees-and-services\/confidentiality-advisory-group\/. 14 Mar 2024."}],"container-title":["BJGP Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3399\/BJGPO.2023.0163","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T14:36:01Z","timestamp":1725633361000},"score":1,"resource":{"primary":{"URL":"http:\/\/bjgpopen.org\/lookup\/doi\/10.3399\/BJGPO.2023.0163"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,1]]},"references-count":21,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,7,29]]},"published-print":{"date-parts":[[2024,7]]}},"alternative-id":["10.3399\/BJGPO.2023.0163"],"URL":"https:\/\/doi.org\/10.3399\/bjgpo.2023.0163","relation":{},"ISSN":["2398-3795"],"issn-type":[{"value":"2398-3795","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,1]]}}}